139 related articles for article (PubMed ID: 27128199)
1. Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children.
Kekitiinwa A; Musiime V; Thomason MJ; Mirembe G; Lallemant M; Nakalanzi S; Baptiste D; Walker AS; Gibb DM; Judd A
Antivir Ther; 2016; 21(7):579-585. PubMed ID: 27128199
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
Musiime V; Fillekes Q; Kekitiinwa A; Kendall L; Keishanyu R; Namuddu R; Young N; Opilo W; Lallemant M; Walker AS; Burger D; Gibb DM
J Acquir Immune Defic Syndr; 2014 Jun; 66(2):148-54. PubMed ID: 24828266
[TBL] [Abstract][Full Text] [Related]
3. Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe.
Pasipanodya B; Kuwengwa R; Prust ML; Stewart B; Chakanyuka C; Murimwa T; Brophy J; Salami O; Mushavi A; Apollo T
J Int AIDS Soc; 2018 Dec; 21(12):e25214. PubMed ID: 30549217
[TBL] [Abstract][Full Text] [Related]
4. Understanding acceptance of and adherence to a new formulation of paediatric antiretroviral treatment in the form of pellets (LPV/r)-A realist evaluation.
Nebot Giralt A; Nöstlinger C; Lee J; Salami O; Lallemant M; Onyango-Ouma W; Nyamongo I; Marchal B
PLoS One; 2019; 14(8):e0220408. PubMed ID: 31433803
[TBL] [Abstract][Full Text] [Related]
5. Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa.
Nahirya-Ntege P; Cook A; Vhembo T; Opilo W; Namuddu R; Katuramu R; Tezikyabbiri J; Naidoo-James B; Gibb D;
PLoS One; 2012; 7(5):e36186. PubMed ID: 22567139
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania.
Jiwa NA; Ketang'enyi E; Nganyanyuka K; Mbwanji R; Mwenisongole D; Masuka E; Brown M; Charles M; Mwasomola DL; Nyangalima T; Olomi W; Komba L; Gwimile J; Kasambala B; Mwita L
PLoS One; 2024; 19(1):e0292424. PubMed ID: 38165867
[TBL] [Abstract][Full Text] [Related]
7. Understanding the acceptability and adherence to paediatric antiretroviral treatment in the new formulation of pellets (LPV/r): the protocol of a realist evaluation.
Nebot Giralt A; Nöstlinger C; Lee J; Salami O; Lallemant M; Ouma O; Nyamongo I; Marchal B
BMJ Open; 2017 Mar; 7(3):e014528. PubMed ID: 28360249
[TBL] [Abstract][Full Text] [Related]
8. Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir.
Chokephaibulkit K; Nuntarukchaikul M; Phongsamart W; Wittawatmongkol O; Lapphra K; Vanprapar N; Cressey TR
J Antimicrob Chemother; 2012 Dec; 67(12):2927-31. PubMed ID: 22923483
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
10. Pursuing use of optimal formulations for paediatric HIV epidemic control - a look at the use of LPV/r oral pellets and oral granules.
Malati CY; Golin R; O'Brien L; Sugandhi N; Srivastava M; Larson C; Phelps BR
J Int AIDS Soc; 2019 Apr; 22(4):e25267. PubMed ID: 30983152
[TBL] [Abstract][Full Text] [Related]
11. Acceptability of a new 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir paediatric fixed-dose combination: the caregiver-child dyads' perspective.
Rotsaert A; Ogara C; Mwanga-Amumpaire J; Kekitiinwa AR; Musiime V; Najjingo E; Kisitu GP; Nazzinda R; Nambi E; Lee J; Diallo M; Kyomuhendo F; Waweru M; Andrieux-Meyer I; Nöstlinger C
Ther Adv Infect Dis; 2023; 10():20499361231159993. PubMed ID: 36968554
[TBL] [Abstract][Full Text] [Related]
12. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P;
Lancet; 2016 Feb; 387(10018):566-573. PubMed ID: 26603917
[TBL] [Abstract][Full Text] [Related]
13. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice.
Gondrie IPE; Bastiaans DET; Fraaij PLA; Driessen GJA; van der Knaap LC; Visser EG; van Jaarsveld P; de Groot R; Hartwig NG; Burger DM; van Rossum AMC
Pediatr Infect Dis J; 2017 Oct; 36(10):976-980. PubMed ID: 28475554
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV drugs lopinavir/ritonavir activate bitter taste receptors.
Chen S; Zhou X; Lu Y; Xu K; Wen J; Cui M
Chem Senses; 2023 Jan; 48():. PubMed ID: 37625013
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
Ramautarsing RA; van der Lugt J; Gorowara M; Sophonphan J; Ananworanich J; Lange JM; Burger DM; Phanuphak P; Ruxthungtham K; Avihingsanon A
Antivir Ther; 2013; 18(2):249-52. PubMed ID: 22908131
[TBL] [Abstract][Full Text] [Related]
16. Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.
Blanche S; Tylleskär T; Peries M; Kankasa C; Engebretsen I; Meda N; Tumwine JK; Singata-Madliki M; Mwiya M; Van de Perre P; Nagot N;
Lancet HIV; 2019 May; 6(5):e307-e314. PubMed ID: 30814028
[TBL] [Abstract][Full Text] [Related]
17. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.
Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V
J Int AIDS Soc; 2017 Apr; 20(1):21362. PubMed ID: 28453240
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.
van der Flier M; Verweel G; van der Knaap LC; van Jaarsveld P; Driessen GJ; van der Lee M; Hartwig NG; Burger DM
Antivir Ther; 2008; 13(8):1087-90. PubMed ID: 19195335
[TBL] [Abstract][Full Text] [Related]
19. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
Venter WDF; Moorhouse M; Sokhela S; Serenata C; Akpomiemie G; Qavi A; Mashabane N; Arulappan N; Sim JW; Sinxadi PZ; Wiesner L; Maharaj E; Wallis C; Boyles T; Ripin D; Stacey S; Chitauri G; Hill A
Lancet HIV; 2019 Jul; 6(7):e428-e437. PubMed ID: 31202690
[TBL] [Abstract][Full Text] [Related]
20. Long-term lopinavir/ritonavir monotherapy in HIV-infected children.
Kosalaraksa P; Ananworanich J; Puthanakit T; Pinyakorn S; Lumbiganon P; Chuanjaroen T; Chobkarjing U; Phanuphak P; Pancharoen C; Bunupuradah T;
Pediatr Infect Dis J; 2013 Apr; 32(4):350-3. PubMed ID: 23190774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
